{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:15:18Z","timestamp":1793146518710,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","gastrojournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1053\/j.gastro.2024.02.050","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T15:53:45Z","timestamp":1712678025000},"page":"90-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["How Future Pharmacologic Therapies for Celiac Disease Will Complement the Gluten-Free Diet"],"prefix":"10.1053","volume":"167","author":[{"given":"Valentina","family":"Discepolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciar\u00e1n P.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Schuppan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2024.02.050_bib1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/nri2670","article-title":"Tissue-mediated control of immunopathology in coeliac disease","volume":"9","author":"Jabri","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.gastro.2024.02.050_bib2","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1053\/j.gastro.2009.09.008","article-title":"Celiac disease: from pathogenesis to novel therapies","volume":"137","author":"Schuppan","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MOG.0000000000000041","article-title":"Advances in coeliac disease","volume":"30","author":"Lundin","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1053\/j.gastro.2024.02.050_bib4","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-020-2003-8","article-title":"IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease","volume":"578","author":"Abadie","year":"2020","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2024.02.050_bib5","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1053\/j.gastro.2021.08.016","article-title":"Co-factors, microbes, and immunogenetics in celiac disease to guide novel approaches for diagnosis and treatment","volume":"161","author":"Verdu","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287662","article-title":"Expression of transglutaminase 2 in human gut epithelial cells: implications for coeliac disease","volume":"18","author":"Amundsen","year":"2023","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2024.02.050_bib7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nm0698-713","article-title":"Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease","volume":"4","author":"Molberg","year":"1998","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2024.02.050_bib8","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.4049\/jimmunol.161.4.1585","article-title":"Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity","volume":"161","author":"van de Wal","year":"1998","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.gastro.2024.02.050_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fimmu.2012.00313","article-title":"The intestinal B-cell response in celiac disease","volume":"3","author":"Mesin","year":"2012","journal-title":"Front Immunol"},{"key":"10.1053\/j.gastro.2024.02.050_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2015.05.013","article-title":"Distinct and synergistic contributions of epithelial stress and adaptive immunity to functions of intraepithelial killer cells and active celiac disease","volume":"149","author":"Setty","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/j.gastro.2019.10.006","article-title":"Identification of a \u03b3c receptor antagonist that prevents reprogramming of human tissue-resident cytotoxic T cells by IL15 and IL21","volume":"158","author":"Ciszewski","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib12","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1080\/00365521.2016.1218540","article-title":"Long-term mucosal recovery and healing in celiac disease is the rule-not the exception","volume":"5","author":"H\u00e6re","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.02.050_bib13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2006.12.006","article-title":"Etiologies and predictors of diagnosis in nonresponsive celiac disease","volume":"5","author":"Leffler","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.02.050_bib14","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/j.1572-0241.2002.05917.x","article-title":"Etiology of nonresponsive celiac disease: results of a systematic approach","volume":"97","author":"Abdulkarim","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.02.050_bib15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2014.07.046","article-title":"Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome","volume":"147","author":"Fritscher-Ravens","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.gastro.2019.03.046","article-title":"Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin E","volume":"157","author":"Fritscher-Ravens","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib17","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.cgh.2022.01.011","article-title":"A\u00a0low FODMAP diet reduces symptoms in treated celiac patients with ongoing symptoms-a randomized controlled trial","volume":"20","author":"van Megen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.02.050_bib18","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3390\/nu9101129","article-title":"Indications and use of the gluten contamination elimination diet for patients with non-responsive celiac disease","volume":"9","author":"Leonard","year":"2017","journal-title":"Nutrients"},{"key":"10.1053\/j.gastro.2024.02.050_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(00)02481-8","article-title":"Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group","volume":"356","author":"Cellier","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.02.050_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ajcn\/85.1.160","article-title":"A\u00a0prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease","volume":"85","author":"Catassi","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1053\/j.gastro.2024.02.050_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.appet.2013.04.016","article-title":"Intentional and inadvertent non-adherence in adult coeliac disease. A cross-sectional survey","volume":"68","author":"Hall","year":"2013","journal-title":"Appetite"},{"key":"10.1053\/j.gastro.2024.02.050_bib22","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2019.12.016","article-title":"Most patients with celiac disease on gluten-free diets consume measurable amounts of gluten","volume":"158","author":"Silvester","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib23","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jada.2010.03.014","article-title":"Gluten contamination of grains, seeds, and flours in the United States: a pilot study","volume":"110","author":"Thompson","year":"2010","journal-title":"J\u00a0Am Diet Assoc"},{"key":"10.1053\/j.gastro.2024.02.050_bib24","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ajg.2014.29","article-title":"Patient perception of treatment burden is high in celiac disease compared with other common conditions","volume":"109","author":"Shah","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.02.050_bib25","first-page":"241","article-title":"Quality of life in coeliac disease is determined by perceived degree of difficulty adhering to a gluten-free diet, not the level of dietary adherence ultimately achieved","volume":"20","author":"Barratt","year":"2011","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"key":"10.1053\/j.gastro.2024.02.050_bib26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1756283X13492580","article-title":"Interest in medical therapy for celiac disease","volume":"6","author":"Tennyson","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2024.02.050_bib27","doi-asserted-by":"crossref","first-page":"20518","DOI":"10.3390\/ijms151120518","article-title":"Gliadin peptides as triggers of the proliferative and stress\/innate immune response of the celiac small intestinal mucosa","volume":"15","author":"Barone","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.gastro.2024.02.050_bib28","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1136\/gutjnl-2021-326560","article-title":"Organoids in gastrointestinal diseases: from experimental models to clinical translation","volume":"71","author":"G\u00fcnther","year":"2022","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.02.050_bib29","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/gut.2009.186361","article-title":"Gliadin-primed CD4+CD45RBlowCD25-T cells drive gluten-dependent small intestinal damage after adoptive transfer into lymphopenic mice","volume":"58","author":"Freitag","year":"2009","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.02.050_bib30","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/j.gastro.2020.01.045","article-title":"Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease","volume":"158","author":"Freitag","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib31","doi-asserted-by":"crossref","first-page":"7440","DOI":"10.4049\/jimmunol.0900233","article-title":"Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells","volume":"182","author":"de Kauwe","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.gastro.2024.02.050_bib32","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.4049\/jimmunol.1100854","article-title":"Sensitization to gliadin induces moderate enteropathy and insulitis in nonobese diabetic-DQ8 mice","volume":"187","author":"Galipeau","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.gastro.2024.02.050_bib33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.gastro.2011.10.038","article-title":"The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues","volume":"142","author":"Pinier","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib34","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1053\/j.gastro.2019.02.028","article-title":"Lactobacilli degrade wheat amylase trypsin inhibitors to reduce intestinal dysfunction induced by immunogenic wheat proteins","volume":"156","author":"Caminero","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib35","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gutjnl-2017-314853","article-title":"Outcome measures in coeliac disease trials: the Tampere recommendations","volume":"67","author":"Ludvigsson","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.02.050_bib36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/73200","article-title":"In\u00a0vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope","volume":"6","author":"Anderson","year":"2000","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2024.02.050_bib37","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/ajg.2011.23","article-title":"Assessing possible celiac disease by an HLA-DQ2-gliadin tetramer test","volume":"106","author":"Brottveit","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.02.050_bib38","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2017.11.006","article-title":"HLA-DQ-gluten tetramer blood test accurately identifies patients with and without celiac disease in absence of gluten consumption","volume":"154","author":"Sarna","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib39","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(22)00428-9","article-title":"Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to\u00a0gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study","volume":"8","author":"Tye-Din","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.02.050_bib40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S2468-1253(17)30110-3","article-title":"Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomized, double-blind, placebo-controlled phase 1 studies","volume":"2","author":"Goel","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.02.050_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661622","article-title":"A\u00a0sensitive whole blood assay detects antigen-stimulated cytokine release from CD4+ T cells and facilitates immunomonitoring in a phase 2 clinical trial of Nexvax2 in coeliac disease","volume":"12","author":"Hardy","year":"2021","journal-title":"Front Immunol"},{"key":"10.1053\/j.gastro.2024.02.050_bib42","unstructured":"US Food and Drug Administration. Celiac disease: developing drugs for adjunctive treatment to a gluten-free diet \u2013 guidance for industry. April 2022. Available at: https:\/\/www.fda.gov\/media\/157682\/download. Accessed May 3, 2024."},{"key":"10.1053\/j.gastro.2024.02.050_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015637","article-title":"A\u00a0universal approach to eliminate antigenic properties of alpha-gliadin peptides in celiac disease","volume":"5","author":"Mitea","year":"2010","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2024.02.050_bib44","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/pbi.12455","article-title":"Targeting of prolamins by RNAi in bread wheat: effectiveness of seven silencing-fragment combinations for obtaining lines devoid of coeliac disease epitopes from highly immunogenic gliadins","volume":"14","author":"Barro","year":"2016","journal-title":"Plant Biotechnol J"},{"key":"10.1053\/j.gastro.2024.02.050_bib45","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.3390\/nu13124548","article-title":"Oral consumption of bread from an RNAi wheat line with strongly silenced gliadins elicits no immunogenic response in a pilot study with celiac disease patients","volume":"13","author":"Guzm\u00e1n-L\u00f3pez","year":"2021","journal-title":"Nutrients"},{"key":"10.1053\/j.gastro.2024.02.050_bib46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.foodres.2017.04.025","article-title":"Food processing and breeding strategies for coeliac-safe and healthy wheat products","volume":"110","author":"Jouanin","year":"2018","journal-title":"Food Res Int"},{"key":"10.1053\/j.gastro.2024.02.050_bib47","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/pbi.12837","article-title":"Low-gluten, nontransgenic wheat engineered with CRISPR\/Cas9","volume":"16","author":"S\u00e1nchez-Le\u00f3n","year":"2018","journal-title":"Plant Biotechnol J"},{"key":"10.1053\/j.gastro.2024.02.050_bib48","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12870-019-1889-5","article-title":"Outlook for coeliac disease patients: towards bread wheat with hypoimmunogenic gluten by gene editing of \u03b1- and \u03b3-gliadin gene families","volume":"19","author":"Jouanin","year":"2019","journal-title":"BMC Plant Biol"},{"key":"10.1053\/j.gastro.2024.02.050_bib49","unstructured":"European Commission. Proposal for a Regulation of the European Parliament and of the Council on plants obtained by certain new genomic techniques and their food and feed, and amending Regulation (EU) 2017\/625. Available at: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A52023PC0411. Accessed May 3, 2024."},{"key":"10.1053\/j.gastro.2024.02.050_bib50","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.gastro.2008.09.016","article-title":"Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium","volume":"136","author":"Pinier","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib51","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1021\/jf205319s","article-title":"In-vitro and in-vivo binding activity of chicken egg yolk immunoglobulin Y (IgY) against gliadin in food matrix","volume":"60","author":"Gujral","year":"2012","journal-title":"J\u00a0Agric Food Chem"},{"key":"10.1053\/j.gastro.2024.02.050_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201800646","article-title":"In situ gluten-chitosan interlocked self-assembled supramolecular architecture reduces T-cell-mediated immune response to gluten in celiac disease","volume":"62","author":"Ribeiro","year":"2018","journal-title":"Mol Nutr Food Res"},{"key":"10.1053\/j.gastro.2024.02.050_bib53","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.3390\/nu12072095","article-title":"Gluten degrading enzymes for treatment of celiac disease","volume":"12","author":"Wei","year":"2020","journal-title":"Nutrients"},{"key":"10.1053\/j.gastro.2024.02.050_bib54","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/j.gastro.2014.02.031","article-title":"Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease","volume":"146","author":"L\u00e4hdeaho","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib55","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1053\/j.gastro.2016.11.004","article-title":"No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease","volume":"152","author":"Murray","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib56","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ygh2.371","article-title":"Latiglutenase treatment for celiac disease: symptom and quality of life improvement for seropositive patients on a gluten-free diet","volume":"1","author":"Syage","year":"2019","journal-title":"GastroHep"},{"key":"10.1053\/j.gastro.2024.02.050_bib57","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1053\/j.gastro.2022.07.071","article-title":"Latiglutenase protects the mucosa and attenuates symptom severity in patients with celiac disease exposed to a gluten challenge","volume":"163","author":"Murray","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib58","doi-asserted-by":"crossref","first-page":"G621","DOI":"10.1152\/ajpgi.00034.2006","article-title":"Highly efficient gluten degradation with a newly identified prolyl\u00a0endoprotease: implications for celiac disease","volume":"291","author":"Stepniak","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1053\/j.gastro.2024.02.050_bib59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/gut.2006.111609","article-title":"Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease","volume":"57","author":"Mitea","year":"2008","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.02.050_bib60","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/jacs.5b08325","article-title":"Engineering of Kuma030: a gliadin peptidase that rapidly degrades immunogenic gliadin peptides in gastric conditions","volume":"137","author":"Wolf","year":"2015","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1053\/j.gastro.2024.02.050_bib61","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1136\/gutjnl-2020-323829","article-title":"Lack of relationship of AT1001 to zonulin and prehaptoglobin-2: clinical implications","volume":"70","author":"Sollid","year":"2021","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.02.050_bib62","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/ajg.2012.211","article-title":"A\u00a0randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge","volume":"107","author":"Leffler","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.02.050_bib63","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1053\/j.gastro.2015.02.008","article-title":"Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial","volume":"148","author":"Leffler","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib64","article-title":"First in human trial of IMU-856, an orally available epigenic modulator of barrier regeneration for the treatment of celiac disease","author":"Daveson","year":"2023","journal-title":"Poster Presented at: United European Gastroenterology Week, October 14\u201317,"},{"key":"10.1053\/j.gastro.2024.02.050_bib65","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nm0797-797","article-title":"Identification of tissue transglutaminase as the autoantigen of celiac disease","volume":"3","author":"Dieterich","year":"1997","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2024.02.050_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2019.113560","article-title":"Substrates, inhibitors, and probes of mammalian transglutaminase 2","volume":"591","author":"Zhuang","year":"2020","journal-title":"Anal Biochem"},{"key":"10.1053\/j.gastro.2024.02.050_bib67","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2032441","article-title":"A\u00a0randomized trial of a transglutaminase 2 inhibitor for celiac disease","volume":"385","author":"Schuppan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.02.050_bib68","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3390\/cells11101667","article-title":"Features of ZED1227: the first-in-class tissue transglutaminase inhibitor undergoing clinical evaluation for the treatment of celiac disease","volume":"11","author":"B\u00fcchold","year":"2022","journal-title":"Cells"},{"key":"10.1053\/j.gastro.2024.02.050_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310815","article-title":"The oral transglutaminase 2 inhibitor ZED1227 accumulates in the villous enterocytes in celiac disease patients during gluten challenge and drug treatment","volume":"24","author":"Isola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.gastro.2024.02.050_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg4925","article-title":"A\u00a0high-affinity human TCR-like antibody detects celiac disease gluten peptide-MHC complexes and inhibits T cell activation","volume":"6","author":"Frick","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1053\/j.gastro.2024.02.050_bib71","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2013.12.023","article-title":"Interleukin 15 and CD4(+) T cells cooperate to promote small intestinal enteropathy in response to dietary antigen","volume":"146","author":"Korneychuk","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib72","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2468-1253(19)30264-X","article-title":"Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study","volume":"4","author":"L\u00e4hdeaho","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.02.050_bib73","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2468-1253(19)30265-1","article-title":"Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study","volume":"4","author":"Cellier","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.02.050_bib74","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/382366a0","article-title":"Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue","volume":"382","author":"Wagner","year":"1996","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2024.02.050_bib75","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1124\/jpet.110.169714","article-title":"Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease","volume":"335","author":"Walters","year":"2010","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1053\/j.gastro.2024.02.050_bib76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molimm.2017.01.006","article-title":"OX40: structure and function \u2013 what questions remain?","volume":"83","author":"Willoughby","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1053\/j.gastro.2024.02.050_bib77","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1053\/j.gastro.2024.02.050_bib78","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1046\/j.1365-2362.2000.00658.x","article-title":"The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis)","volume":"30","author":"St\u00fcber","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"10.1053\/j.gastro.2024.02.050_bib79","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.4049\/jimmunol.167.12.6717","article-title":"Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation","volume":"167","author":"Wang","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.gastro.2024.02.050_bib80","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41591-019-0403-9","article-title":"Distinct phenotype of CD4+ T cells driving celiac disease identified in multiple autoimmune conditions","volume":"25","author":"Christophersen","year":"2019","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2024.02.050_bib81","first-page":"132","article-title":"Advances in nonresponsive and refractory celiac disease","volume":"167","author":"Malamut","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib82","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s10620-020-06454-5","article-title":"Enteric-release budesonide may be useful in the management of non-responsive celiac disease","volume":"66","author":"Therrien","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2024.02.050_bib83","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ajg.2017.71","article-title":"Open-capsule budesonide for refractory celiac disease","volume":"112","author":"Mukewar","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.02.050_bib84","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1111\/j.1572-0241.2007.01380.x","article-title":"Budesonide in the treatment of refractory celiac disease","volume":"102","author":"Brar","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.02.050_bib85","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.cgh.2019.03.029","article-title":"Efficacy of enteric-release oral budesonide in treatment of acute reactions to gluten in patients with celiac disease","volume":"18","author":"Therrien","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.02.050_bib86","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cgh.2010.04.009","article-title":"Celiac crisis is a rare but serious complication of celiac disease in adults","volume":"8","author":"Jamma","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.02.050_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001012","article-title":"Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease","volume":"2","author":"Tye-Din","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2024.02.050_bib88","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib89","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.nano.2018.10.001","article-title":"Overcoming challenges in treating autoimmuntity: development of tolerogenic immune-modifying nanoparticles","volume":"18","author":"Pearson","year":"2019","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10.1053\/j.gastro.2024.02.050_bib90","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nri2858","article-title":"Antigen-presenting cell function in the tolerogenic liver environment","volume":"10","author":"Thomson","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.gastro.2024.02.050_bib91","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41551-019-0424-1","article-title":"Synthetically glycosylated antigens induce antigen-specific tolerance and prevent the onset of diabetes","volume":"3","author":"Wilson","year":"2019","journal-title":"Nat Biomed Eng"},{"key":"10.1053\/j.gastro.2024.02.050_bib92","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S2468-1253(23)00107-3","article-title":"Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial","volume":"8","author":"Murray","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.02.050_bib93","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2015.01.006","article-title":"Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice","volume":"62","author":"Carambia","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2024.02.050_bib94","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/MPG.0000000000002497","article-title":"European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020","volume":"70","author":"Husby","year":"2020","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1053\/j.gastro.2024.02.050_bib95","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/cei.12366","article-title":"Intestinal titres of anti-tissue transglutaminase 2 antibodies correlate positively with mucosal damage degree and inversely with gluten-free diet duration in coeliac disease","volume":"177","author":"Tosco","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1053\/j.gastro.2024.02.050_bib96","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1007\/s00431-022-04535-3","article-title":"Evaluation of mucosal status in the follow-up of pediatric patients with celiac disease: the role of serology","volume":"181","author":"Sengul","year":"2022","journal-title":"Eur J Pediatr"},{"key":"10.1053\/j.gastro.2024.02.050_bib97","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3748\/wjg.v27.i13.1311","article-title":"Non-responsive celiac disease in children on a gluten free diet","volume":"27","author":"Veeraraghavan","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.02.050_bib98","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/j.gastro.2019.04.004","article-title":"Progression of celiac disease in children with antibodies against tissue transglutaminase and normal duodenal architecture","volume":"157","author":"Auricchio","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib99","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.02.050_bib100","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1053\/j.gastro.2022.04.030","article-title":"Prediction models for celiac disease development in children from high-risk families: data from the PreventCD cohort","volume":"163","author":"Meijer","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib101","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/j.gastro.2022.07.086","article-title":"AGA clinical practice update on management of refractory celiac disease:\u00a0expert review","volume":"163","author":"Green","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.02.050_bib102","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1126\/science.adg7505","article-title":"Restoring tolerance with antigen delivery","volume":"383","author":"Jabri","year":"2024","journal-title":"Science"},{"key":"10.1053\/j.gastro.2024.02.050_bib103","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nri3407","article-title":"Triggers and drivers of autoimmunity: lessons from coeliac disease","volume":"13","author":"Sollid","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.gastro.2024.02.050_bib104","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/imr.13071","article-title":"Activation pathways that drive CD4+ T cells to break tolerance in autoimmune diseases","volume":"307","author":"Krovi","year":"2022","journal-title":"Immunol Rev"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524004165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524004165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T09:07:39Z","timestamp":1718183259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508524004165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0016508524004165"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2024.02.050","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How Future Pharmacologic Therapies for Celiac Disease Will Complement the Gluten-Free Diet","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2024.02.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}